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Background: The aim of this analysis was to estimate biochemical parameters and the costs 
of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 
study.
Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for 
SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemi-
cal parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to 
hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from 
the Italian National Health Service perspective.
Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) 
and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous 
paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. 
At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group 
(P,0.0001). At the second survey, the intravenous paricalcitol group showed a higher percentage 
of patients at target for PTH than in the oral calcitriol group without changing the percentage 
of patients at target for phosphate. Moreover, between baseline and the second survey, intra-
venous paricalcitol significantly increased both the percentage of patients at target for PTH 
(P=0.033) and the percentage of patients at target for the combined endpoint PTH, calcium, and 
phosphate (P=0.001). The per-patient weekly pharmaceutical costs related to SHPT treatment, 
erythropoietin-stimulating agents and phosphate binders accounted for 186.32€ and 219.94€ at 
baseline for oral calcitriol and intravenous paricalcitol, respectively, while after 6 months, the 
costs were 180.51€ and 198.79€, respectively. Either at the beginning of dialysis or 6 months 
later, the total cost of SHPT treatment was not significantly lower in the oral calcitriol group 
compared with the intravenous paricalcitol group, with a difference among groups that decreased 
by 46% between the two observations. The cost of erythropoietin stimulating agents at the second 
survey was lower (-22%) in the intravenous paricalcitol group than in the oral calcitriol group 
(132.13€ versus 168.36€, respectively).
Conclusion: Intravenous paricalcitol significantly increased the percentage of patients at target 
for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treat-
ment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was 
not significantly higher than the cost for patients treated with oral calcitriol.
Keywords: cost consequences analysis, therapeutic costs, outcomes, SHPT treatments, 
secondary hyperparathyroidism
Introduction
Chronic kidney disease (CKD) in all its stages is a relevant public health problem, recog-
nized in 2011 by the World Health Organization as one of the chronic  noncommunicable 
International Journal of Nephrology and Renovascular Disease 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2
Roggeri et al
diseases to fight in the coming decades and identified by 
the Centers for Disease Control and Prevention as a major 
medical priority in recent years.1
CKD is not only a clinical concern, but also a grow-
ing economic and organizational problem, as renal 
replacement therapy consumes a considerable propor-
tion of health care resources. This problem in Italy is 
virtually unknown to the public and is still little known 
and largely underestimated by physicians and governing 
health authorities. The Italian Registry of Dialysis and 
Transplantation reported that the prevalence of patients 
on hemodialysis was 788 per million population, while the 
incidence was 162 per million population, corresponding 
to 42,488 patients on hemodialysis, 8,638 of whom are 
incident patients.2
CKD often affects elderly patients and is associated with 
important comorbidities (cardiac, vascular, osteoarticular, 
neuromuscular), with a relevant impact on patients’ quality 
of life;3–6 a recent Italian study revealed that dialysis patients 
perceived an impaired quality of life, and hemodialysis 
patients in particular noticed a worse quality of life compared 
with peritoneal dialysis patients.7
From the economic point of view, in the USA, total Medi-
care expenditures for end-stage renal disease (ESRD) reached 
$33 billion in 2010, accounting for more than 6% of the total 
Medicare budget. About 1.3% of Medicare patients had ESRD 
in 2010, yet accounted for 7.5% of Medicare spending. Medi-
care costs for ESRD were $75,000 per patient per year.8
Worldwide, several studies have reported relevant costs 
in the charge to health services associated with the treatment 
of ESRD patients;9–14 in Italy, these average yearly costs per 
hemodialysis patient were reported to range from about 
36,000€ to 50,000€ (depending on the type of resources 
considered in the studies).
Secondary hyperparathyroidism (SHPT) is a frequent 
comorbidity in CKD and ESRD patients, and leads to bone 
and mineral metabolism disorders. Bone diseases represent 
only one of the consequences of SHPT, whereas the most 
dreaded are cardiovascular diseases and their increased risk 
of morbidity and mortality in these patients.15–18 The present 
study is a subanalysis of the FARO-2 survey conducted in 
Italy. It is aimed at complementing the FARO project results 
with data regarding: the therapeutic management of SHPT 
in the period April 2008 to October 2008 in a subgroup of 
patients who started hemodialysis during the FARO project; 
comorbidities, hospitalizations, deaths and the percentage 
of patients within the ranges recommended by the Kidney 
Disease Outcomes Quality Initiative guidelines.
The present subanalysis evaluated the pharmaceutical 
costs of treatment and the evolution of bone and mineral 
parameters in patients new to hemodialysis who maintained 
the same SHPT treatment for the first 6 months following 
the start of dialysis.
Patients and methods
The FARO-2 was a retrospective observational sur-
vey in which all patients who had started hemodialysis 
 treatment #8 months earlier were enrolled. A questionnaire 
containing data related to clinical and laboratory parameters 
and to hospitalization for any reason during the week pre-
ceding each observation was filled in by the physician for 
each patient (all patients signed a written informed consent 
form as per Italian Legislative Decree 196/2003, with patient 
data used in an anonymous way) and the FARO-2 survey 
was approved by the ethical committees for each of the 
26 participant centers.
The FARO-2 involved 26 of the 28 dialysis centers 
(two centers did not enrolled incident patients) already 
participating in the FARO survey; the distribution of cen-
ters was representative of the Italian national situation. 
A total of 568 patients were enrolled. For the purposes of 
this subanalysis, patients maintaining the same treatment 
at the beginning of dialysis and at the subsequent survey 
(6 months later) were selected. Patients were grouped and 
analyzed per type of SHTP treatment. Patients for whom no 
data had been collected at both observation points or who 
had received different SHPT treatment at the two observation 
points were excluded from this analysis.
Bone and mineral parameters considered for evaluation 
of clinical effectiveness included serum parathyroid hor-
mone (PTH), calcium, and phosphorus. Target levels for 
serum PTH, calcium, and phosphorus were in accordance 
with the National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative international guidelines (revised 
in 2003) and with the contemporary national guidelines.19 
Target levels indicated by the reported guidelines were 
150–300 pg/mL for intact PTH, 3.5–5.5 mg/dL for phos-
phorus, and 8.4–9.5 mg/dL for calcium.
Patients’ demographic characteristics and data related 
to the presence of comorbidities, pharmacological treat-
ments, and biochemical parameters were recorded at 
baseline and 6 months later (second survey). The selected 
subpopulations were analyzed for evolution of biochemi-
cal parameters, percentage of patients reaching target level 
for each biochemical parameter, SHPT drug consumption, 
association with other drugs, and related pharmaceutical 
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costs. With regard to resource consumption, we evaluated 
drugs reimbursed for the treatment of SHPT, ie, phosphate 
binders (calcium-based and sevelamer) and erythropoietin-
stimulating agents (ESA).
For this cost consequence analysis, the weekly cost of 
pharmacological treatment per group was estimated. The 
analysis was performed from the Italian National Health 
Service perspective. Thus, for hospital drugs, the maximum 
approved selling prices to Italian National Health Service 
were considered (reference year 2008) while, for retail 
drugs, the approved reimbursement price was considered; 
all prices are pretransient compulsory reductions and include 
negotiated discounts published in the official Italian bul-
letin.  Unitary costs considered was 93€ for an intravenous 
paricalcitol pack (five vials, 1 mL, 5 µg/mL, including 
published negotiated discount to public structure of 7.92%) 
and 5.51€ for an oral calcitriol pack (30 tablets, 0.25 µg); 
reported prices are pre every transient reduction of prices 
(in Italy two compulsory price reductions of 5% and 5% are 
applied to all reimbursed drugs).
Comparisons between treatment groups were assessed 
by measuring disease severity as baseline PTH levels; the 
effectiveness of treatment was expressed in terms of PTH 
decrease (difference from baseline to the second survey).
Results
Among the entire FARO-2 population, two prominent cohorts 
of patients were identified, ie, oral calcitriol (n=105) and 
intravenous paricalcitol (n=33); intravenous calcitriol (n=5) 
and intravenous paricalcitol + cinacalcet combination (n=2) 
cohorts were not analyzed because of the small size of the 
samples. In both groups analyzed, the majority of patients 
were males and the average age was slightly higher in the 
intravenous paricalcitol group versus the calcitriol group 
(68.7 versus 65.6 years). Baseline demographic characteris-
tics for the different treatment groups at the start of dialysis 
are summarized in Table 1.
In terms of comorbidities, as reported in Table 1, hyper-
tension and cancer were more frequent in patients on oral 
calcitriol, whereas cardiac pathologies, dyslipidemia, and 
diabetes were more frequent in patients on intravenous 
paricalcitol.
As reported in Table 2, the baseline biochemical profiles 
of patients in the two cohorts were significantly different with 
regard to PTH level (according to Kidney Disease Outcomes 
Quality Initiative guideline targets; P,0.0001), phosphorus 
level at baseline (P=0.0041), percentage of patients at tar-
get for PTH level at baseline (P,0.0001), and percentage 
of patients at target for phosphorus level (P=0.009). No 
significant differences were reported for calcium levels 
and percentages of patients at target for this parameter at 
baseline. PTH levels decreased significantly from baseline 
to the second survey in both groups (P=0.0024 in the oral 
calcitriol group and P=0.0025 in the intravenous paricalcitol 
group), calcium levels increased significantly in both groups 
(P=0.0046 in the oral calcitriol group and P=0.0255 in the 
intravenous paricalcitol group), and phosphorus levels did not 
change significantly between the two observation points.
At the second survey, the percentage of patients reported 
to be at target for PTH was slightly higher in the intravenous 
paricalcitol group than in the oral calcitriol group, despite 
a significantly lower percentage of intravenous paricalcitol 
patients than oral calcitriol patients being at target at baseline 
(18.2% versus 34.4%, respectively, P,0.0001); percentages 
of patients at target for phosphorus showed a trend towards 
an increase in the intravenous paricalcitol group, but a slight 
decrease in the oral calcitriol group (at the first survey, the 
percentage of patients at target for phosphorus was signifi-
cantly higher in the oral calcitriol group [P=0.009], without 
a significant difference at the second survey). Percentages 
of patients at target for calcium increased slightly in both 
groups, without significant differences versus baseline. 
Moreover, between the first and second survey, intravenous 
paricalcitol significantly increased the percentage of patients 
at target for PTH (18.2% at baseline versus 45.5% at the 
second survey; P=0.033) and significantly increased the 
percentage of patients at target for the combined endpoint of 
PTH, calcium, and phosphorus (3.0% to 12.1%; P=0.001).
Weekly pharmaceutical costs for SHPT treatment per 
patient accounted for 1.23€ at baseline and 1.20€ at the second 
Table 1 Demographic characteristics
PO calcitriol IV paricalcitol
Patients with same shPT  
therapy (n)
105 33
age, years (sD) 65.5 (16.4) 68.7 (16.4)
sex, n (%)
 Females 33 (31.1%) 11 (33.3%)
 Males 73 (68.9%) 22 (66.7%)
Baseline comorbidities (%)
 hypertension 81.1 66.7
 Vascular pathology 22.6 27.3
 cardiac pathology 36.8 48.5
 liver pathology 3.8 3.0
 Dyslipidemia 17.9 39.4
 cancer 5.7 3.0
 Diabetes 20.8 30.3
Abbreviations: PO, oral; IV, intravenous; sD, standard deviation; shPT, secondary 
hyperparathyroidism.
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Table 2 Biochemical parameters
PO calcitriol (n=105) IV paricalcitol (n=33)
Baseline,  
mean (SD)
Second survey, 
mean (SD)
Baseline,  
mean (SD)
Second survey, 
mean (SD)
PTh level (pg/ml) 289.4a,e (168.4) 237.2e (128.8) 503.9a,f (291.9) 348.7f (170.6)
ca level (mg/dl) 8.7g (0.6) 8.9g (0.6) 8.7h (0.7) 8.9h (0.6)
P level (mg/dl) 4.7b (1.1) 5.0 (1.2) 5.3b (1.2) 5.3 (1.1)
ca × P 40.9 (10) 44.4 (10.9) 46.3 (11.9) 47.3 (10.9)
% patients at target for PTh 34.4%c 42.6% 18.2%c,i 45.5%i
% patients at target for ca 50.0% 56.2% 42.4% 45.5%
% patients at target for P 65.7%d 61.0% 39.4%d 51.5%
% patients at target PTh, ca and P 13.2% 13.2% 3.0%j 12.1%j
Notes: aP,0.0001, bP=0.0041, cP,0.0001, dP=0.009, eP=0.0024, fP=0.0025, gP=0.0046, hP=0.0255, iP=0.033, jP,0.001. 
Abbreviations: PO, oral; IV, intravenous; sD, standard deviation; PTh, parathyroid hormone; ca, calcium; P, phosphorus.
Table 3 cost analysis in pateints treated with oral calcitriol or intravenous paricaclcitol
PO calcitriol (n=105) IV paricalcitol (n=33)
Baseline Survey 2 Baseline Survey 2
shPT treatment (€) 1.23 1.20 42.97 37.46
sevelamer
 Percentage of patients treated 18.9% 19.8% 63.6% 69.7%
 average (sD) daily dosage, mg 2,600.00 (1,066.20) 3,733.33 (2,151.6) 2,791.40 (1,217.0) 3,272.70 (1,499.90)
  average weekly expenditure for  
percentage of patients treated (€)
6.21 9.34 23.87 28.82
calcium-based phosphate binders
 Percentage of patients treated 65.1% 66.0% 27.3% 18.2%
 average (sD) daily dosage, mg 1,941.20 (1,024.10) 2,097.80 (1,156.2) 1,687.50 (593.9) 1,800.00 (758.30)
  average weekly expenditure for  
percentage of patients treated (€)
1.47 1.61 0.53 0.38
epoietin     
 Percentage of patients treated 96.2% 93.4% 87.9% 84.8%
 average (sD) daily dosage, IU 10,064.00 (7,696.60) 9,837.00 (7,632.80) 9,472.40 (5,339.2) 8,503.20 (8,144.5)
  average weekly expenditure for  
percentage of patients treated (€)
177.41 168.36 152.57 132.13
 Total weekly cost of treatment (€) 186.32 180.51 219.94 198.79
Abbreviations: PO, oral; IV, intravenous; sD, standard deviation; shPT, secondary hyperparathyroidism.
survey for oral calcitriol, and 42.97€ at baseline versus 37.46€ 
at the second survey for intravenous paricalcitol.
Considering that phosphate binders (calcium-based and 
sevelamer) and ESA are a substantial part of the treatment 
of SHPT patients, the overall costs of treatment were cal-
culated (Table 3). Total weekly costs per patient, including 
for vitamin D, ESA, and phosphate binders, accounted for 
186.32€ at baseline and 180.51€ at the second survey for 
oral calcitriol and for 219.94€ at baseline and 198.79€ at the 
second survey for intravenous paricalcitol.
The total cost of SHPT treatment was not significantly 
lower in the oral calcitriol group than in the intravenous pari-
calcitol group, either at the beginning of dialysis or 6 months 
later, with a difference between groups that decreased by 
46% between the two observations (186.32€ versus 219.94€ 
at baseline, P=0.058; 180.51€ versus 198.79€ after 6 months, 
P=0.325, respectively). The cost of ESA at the second survey 
was lower (-22%) in the intravenous paricalcitol group than 
in the oral calcitriol group (132.13€ versus 168.36€, respec-
tively), although statistical significance was not reached 
(P=0.061). The percentages of patients treated with ESA and 
average daily doses were lower in the intravenous paricalcitol 
group than in the oral calcitriol group both at baseline and 
at the second survey.
Discussion
In terms of effectiveness of the two treatments, both oral 
calcitriol and intravenous paricalcitol led to a significant 
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reduction in PTH levels, but only intravenous paricalcitol 
led to a significant increase in the percentage of patients at 
target for PTH levels (from 18.2% at baseline to 45.5% at 
second survey; P=0.033) and to a significant increase in the 
percentage of patients at target at the same time points for 
PTH, calcium, and phosphorus (from 3.0% at baseline to 
12.1% at second survey; P=0.001).
This study highlights that costs related to health care 
resource utilization, as already reported in a European Union 
study20 and a US study,21 increased with rising baseline PTH. 
Confirming the findings of the cost consequences analysis 
of the FARO survey22 performed on the overall hemodialysis 
population, the present study showed that different baseline 
severity of SHPT in terms of PTH level was associated with 
different treatment patterns. Oral calcitriol, in fact a low cost 
therapeutic option, was used effectively in significantly less 
severe patients than intravenous paricalcitol (see Table 2) in 
terms of baseline PTH level and of baseline percentages of 
patients at target for all bone mineral parameters (PTH, cal-
cium, and phosphorus) that were higher in the oral calcitriol 
group than in the intravenous paricalcitol group. Despite 
these differences in disease severity between the two groups 
at baseline (PTH level at baseline was almost double in the 
intravenous paricalcitol group compared with the oral calcit-
riol group), the total pharmaceutical weekly costs (including 
for  vitamin D, ESA, and phosphate binders) were similar in 
the two groups, with a difference that decreased between 
baseline and the second survey.
This study also highlights the relevance in terms of costs 
of therapies associated with vitamin D in the treatment of 
SHPT (ESA and phosphate binders), ie, oral calcitriol therapy 
accounted for about 0.7% of total costs, while intravenous 
paricalcitol accounted for about 19% of total costs both at 
baseline and at the second survey.
The structure of the FARO-2 study is the most important 
limitation of the present analysis. The study was not con-
trolled and lacks comparability between cohorts, although 
it reflects the treatment pathways at the time of the survey. 
Moreover, a priori, we hypothesized that patients who 
remained on the same treatment between baseline and the 
second survey would remain on the same treatment in the 
period between the two observations (in fact, because data 
were collected in one survey every 6 months, there was no 
indication of resource consumption for the period between 
the two surveys). Finally, the selection of cohorts of patients 
who remained on the same treatment between the two surveys 
resulted in a reduction of sample size, but allows an economic 
evaluation for the different treatment cohorts. It should also 
be considered that, because these patients are frequently on 
multidrug therapy, their compliance with oral drugs could be 
suboptimal and could negatively affect the efficacy of oral 
pharmacological therapies.
Other important limitations of this study are related to 
the survey design, in that it was not controlled and lacked 
comparability between cohorts; however, it is reflective of 
real Italian practice patterns at the time of the study. Finally, 
considering the relatively small sample size,  further studies 
of this topic in a wider population could be helpful to confirm 
the results of the present analysis.
Conclusion
The present analysis, performed in a subpopulation of the 
FARO-2 survey, was conducted to evaluate the biochemical 
consequences and overall costs of pharmacological treatment 
in patients new to dialysis and affected by SHPT. Among the 
two identified groups, only intravenous paricalcitol signifi-
cantly increased the percentage of patients at target for the 
combined endpoint PTH, Ca, and P (p=0.001) and the total 
cost of treatment of the  intravenous paricalcitol patients after 
six months from dialysis entrance was not significantly higher 
than in the oral calcitriol patients.
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